{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:39:42Z","timestamp":1789720782393,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40121-025-01194-3","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T11:12:35Z","timestamp":1753269155000},"page":"1953-1972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants\u2019 First RSV Season in the UK"],"prefix":"10.1007","volume":"14","author":[{"given":"Mersha","family":"Chetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Yarnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Musci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Ghemmouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"1","key":"1194_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/cmr.00010-16","volume":"30","author":"C Griffiths","year":"2017","unstructured":"Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev. 2017;30(1):277\u2013319. https:\/\/doi.org\/10.1128\/cmr.00010-16.","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"1194_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jinf.2019.02.012","volume":"78","author":"RM Reeves","year":"2019","unstructured":"Reeves RM, Hardelid P, Panagiotopoulos N, Minaji M, Warburton F, Pebody R. Burden of hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: a data linkage modelling study. J Infect. 2019;78(6):468\u201375. https:\/\/doi.org\/10.1016\/j.jinf.2019.02.012.","journal-title":"J Infect"},{"issue":"6","key":"1194_CR3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","volume":"360","author":"CB Hall","year":"2009","unstructured":"Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588\u201398. https:\/\/doi.org\/10.1056\/NEJMoa0804877.","journal-title":"N Engl J Med"},{"issue":"10098","key":"1194_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/s0140-6736(17)30938-8","volume":"390","author":"T Shi","year":"2017","unstructured":"Shi T, McAllister DA, O\u2019Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946\u201358. https:\/\/doi.org\/10.1016\/s0140-6736(17)30938-8.","journal-title":"Lancet"},{"key":"1194_CR5","unstructured":"UK Health Security Agency. Respiratory syncytial virus: the green book, chapter 27a. Secondary Respiratory syncytial virus: the green book, chapter 27a 2015. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/458469\/Green_Book_Chapter_27a_v2_0W.PDF. Accessed 1 Mar 2025."},{"issue":"7","key":"1194_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1136\/jech.2004.026450","volume":"59","author":"DM Fleming","year":"2005","unstructured":"Fleming DM, Pannell RS, Cross KW. Mortality in children from influenza and respiratory syncytial virus. J Epidemiol Community Health. 2005;59(7):586\u201390. https:\/\/doi.org\/10.1136\/jech.2004.026450.","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"1194_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/INF.0b013e31822e68e6","volume":"31","author":"LJ Stockman","year":"2012","unstructured":"Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997\u20132006. Pediatr Infect Dis J. 2012;31(1):5\u20139. https:\/\/doi.org\/10.1097\/INF.0b013e31822e68e6.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"1194_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.12968\/jfch.2024.1.2.65","volume":"1","author":"W Carroll","year":"2024","unstructured":"Carroll W, Adams E, Evans K, Holmes S, Carreno M. Respiratory syncytial virus: understanding the patient journey and healthcare burden. J Fam Child Health. 2024;1(2):65\u201371. https:\/\/doi.org\/10.12968\/jfch.2024.1.2.65.","journal-title":"J Fam Child Health"},{"issue":"1","key":"1194_CR9","first-page":"2","volume":"10","author":"F Fusco","year":"2022","unstructured":"Fusco F, Hocking L, Stockwell S, et al. The burden of respiratory syncytial virus: understanding impacts on the NHS, society and economy. Rand Health Q. 2022;10(1):2.","journal-title":"Rand Health Q"},{"key":"1194_CR10","unstructured":"Business Wire. MHRA grants approval of Beyfortus\u00ae (nirsevimab) for prevention of RSV disease in infants: Business Wire; 2022."},{"key":"1194_CR11","unstructured":"Medicines and Healthcare Products Regulatory Agency. RSV vaccination of pregnant women for infant protection: information for healthcare practitioners. Secondary RSV vaccination of pregnant women for infant protection: information for healthcare practitioners. 2024. https:\/\/www.gov.uk\/government\/publications\/respiratory-syncytial-virus-rsv-programme-information-for-healthcare-professionals\/rsv-vaccination-of-pregnant-women-for-infant-protection-information-for-healthcare-practitioners#:~:text=Recommended%20vaccines,-Abrysvo%C2%AE%20Pre&text=Abrysvo%C2%AE%20was%20licensed%20in,in%20over%204%2C000%20pregnant%20women. Accessed 1 Mar 2025."},{"issue":"8","key":"1194_CR12","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1016\/S2468-2667(17)30103-2","volume":"2","author":"D Cromer","year":"2017","unstructured":"Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Pub Health. 2017;2(8):e367\u201374. https:\/\/doi.org\/10.1016\/S2468-2667(17)30103-2.","journal-title":"Lancet Pub Health"},{"issue":"9","key":"1194_CR13","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.vaccine.2023.01.058","volume":"41","author":"AM Getaneh","year":"2023","unstructured":"Getaneh AM, Li X, Mao Z, et al. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: evaluation for six European countries. Vaccine. 2023;41(9):1623\u201331. https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.058.","journal-title":"Vaccine"},{"issue":"1","key":"1194_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12916-020-01537-6","volume":"18","author":"X Li","year":"2020","unstructured":"Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Med. 2020;18(1):82. https:\/\/doi.org\/10.1186\/s12916-020-01537-6.","journal-title":"BMC Med"},{"issue":"49","key":"1194_CR15","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1016\/j.vaccine.2022.10.041","volume":"40","author":"D Hodgson","year":"2022","unstructured":"Hodgson D, Koltai M, Krauer F, Flasche S, Jit M, Atkins KE. Optimal respiratory syncytial virus intervention programmes using nirsevimab in England and Wales. Vaccine. 2022;40(49):7151\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.041.","journal-title":"Vaccine"},{"key":"1194_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100829","volume":"38","author":"D Hodgson","year":"2024","unstructured":"Hodgson D, Wilkins N, van Leeuwen E, et al. Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination. Lancet Reg Health Eur. 2024;38: 100829. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100829.","journal-title":"Lancet Reg Health Eur"},{"key":"1194_CR17","unstructured":"Noble M, Ali Khan R, Walker B, Bennett E, Gent N. Hospitalisation rates associated with respiratory syncytial virus (RSV) infection in children \u2264 24 months in England, 2015\u20132019. In: 42nd annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), Copenhagen, Denmark; 2024."},{"key":"1194_CR18","unstructured":"Office for National Statistics (ONS). CPIH INDEX 06: health 2015=100. Secondary CPIH INDEX 06: health 2015=100. 2024. https:\/\/www.ons.gov.uk\/economy\/inflationandpriceindices\/timeseries\/l528\/mm23. Accessed 1 Mar 2025."},{"key":"1194_CR19","unstructured":"National Health Service England. 2019\/20 National Cost Collection Data Publication. Secondary 2019\/20 National Cost Collection Data Publication. https:\/\/www.england.nhs.uk\/publication\/2019-20-national-cost-collection-data-publication\/. Accessed 1 Mar 2025."},{"key":"1194_CR20","unstructured":"Personal Social Services Research Unit. Unit Costs of Health and Social Care 2020. Secondary Unit Costs of Health and Social Care 2020. https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2020\/. Accessed 1 Mar 2025."},{"issue":"10","key":"1194_CR21","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s40121-024-01037-7","volume":"13","author":"A Kieffer","year":"2024","unstructured":"Kieffer A, Beuvelet M, Moncayo G, et al. Disease burden associated with all infants in their first RSV season in the UK: a static model of universal immunization with nirsevimab against RSV-related outcomes. Infect Dis Ther. 2024;13(10):2135\u201353. https:\/\/doi.org\/10.1007\/s40121-024-01037-7.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"1194_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1913556.","journal-title":"N Engl J Med"},{"issue":"9","key":"1194_CR23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2110275.","journal-title":"N Engl J Med"},{"issue":"3","key":"1194_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/s2352-4642(22)00321-2","volume":"7","author":"EAF Sim\u00f5es","year":"2023","unstructured":"Sim\u00f5es EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180\u20139. https:\/\/doi.org\/10.1016\/s2352-4642(22)00321-2.","journal-title":"Lancet Child Adolesc Health"},{"key":"1194_CR25","unstructured":"Joint Committee on Vaccination and Immunisation (JCVI). Joint Committee on Vaccination and Immunisation Statement on immunisation for Respiratory Syncytial Virus, 2010."},{"issue":"2","key":"1194_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.vaccine.2019.10.023","volume":"38","author":"G Rainisch","year":"2020","unstructured":"Rainisch G, Adhikari B, Meltzer MI, Langley G. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. Vaccine. 2020;38(2):251\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.023.","journal-title":"Vaccine"},{"key":"1194_CR27","unstructured":"BEYFORTUS (nirsevimab-alip) Prescribing Information. Sanofi Pasteur, Inc., Swiftwater, PA18370, USA. 2024. https:\/\/products.sanofi.us\/beyfortus\/beyfortus.pdf. Accessed 1 Mar 2025."},{"key":"1194_CR28","unstructured":"European Medicines Agency. Summary of Product Characteristics: Beyfortus. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beyfortus-epar-product-information_en.pdf. Accessed 1 Mar 2025."},{"issue":"26","key":"1194_CR29","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","volume":"389","author":"SB Drysdale","year":"2023","unstructured":"Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2309189.","journal-title":"N Engl J Med"},{"issue":"11","key":"1194_CR30","doi-asserted-by":"publisher","first-page":"CD013757","DOI":"10.1002\/14651858.CD013757.pub2","volume":"11","author":"L Garegnani","year":"2021","unstructured":"Garegnani L, Styrmisd\u00f3ttir L, Rodriguez PR, Liquitay CME, Esteban I, Franco JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021;11(11):CD013757. https:\/\/doi.org\/10.1002\/14651858.CD013757.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1194_CR31","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1056\/NEJMc2112186","volume":"386","author":"J Domachowske","year":"2022","unstructured":"Domachowske J, Madhi SA, Sim\u00f5es EAF, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022;386(9):892\u20134. https:\/\/doi.org\/10.1056\/NEJMc2112186.","journal-title":"N Engl J Med"},{"key":"1194_CR32","doi-asserted-by":"publisher","first-page":"CD006602","DOI":"10.1002\/14651858.CD006602.pub4","volume":"4","author":"T Andabaka","year":"2013","unstructured":"Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602. https:\/\/doi.org\/10.1002\/14651858.CD006602.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"1194_CR33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2216480.","journal-title":"N Engl J Med"},{"key":"1194_CR34","unstructured":"European Medicines Agency. Summary of Product Characteristics: Abyrsvo, 2023."},{"key":"1194_CR35","unstructured":"Bivalent RSV Prefusion F vaccine for maternal immunization to protect infants; 2023. Food and Drug Administration."},{"key":"1194_CR36","unstructured":"UK Health Security Agency. Quarterly vaccination coverage statistics for children aged up to 5 years in the UK (COVER programme): July to September 2021. Secondary Quarterly vaccination coverage statistics for children aged up to 5 years in the UK (COVER programme): July to September 2021. 2021. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1065452\/hpr2021_COVER.pdf."},{"key":"1194_CR37","unstructured":"Department of Health and Social Care. Respiratory syncytial virus (RSV) immunisation programme for infants and older adults: JCVI full statement, 11 September 2023, 2023."},{"issue":"4","key":"1194_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s2213-2600(22)00414-3","volume":"11","author":"JG Wildenbeest","year":"2023","unstructured":"Wildenbeest JG, Billard MN, Zuurbier RP, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341\u201353. https:\/\/doi.org\/10.1016\/s2213-2600(22)00414-3.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"1194_CR39","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1080\/13696998.2020.1836923","volume":"23","author":"O Narayan","year":"2020","unstructured":"Narayan O, Bentley A, Mowbray K, et al. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. J Med Econ. 2020;23(12):1640\u201352. https:\/\/doi.org\/10.1080\/13696998.2020.1836923.","journal-title":"J Med Econ"},{"issue":"4","key":"1194_CR40","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1067\/s0022-3476(03)00454-2","volume":"143","author":"TF Feltes","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532\u201340. https:\/\/doi.org\/10.1067\/s0022-3476(03)00454-2.","journal-title":"J Pediatr"},{"key":"1194_CR41","doi-asserted-by":"crossref","unstructured":"The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531\u20137","DOI":"10.1542\/peds.102.3.531"},{"issue":"4","key":"1194_CR42","doi-asserted-by":"publisher","first-page":"2079322","DOI":"10.1080\/21645515.2022.2079322","volume":"18","author":"E Baraldi","year":"2022","unstructured":"Baraldi E, Checcucci Lisi G, Costantino C, et al. RSV disease in infants and young children: can we see a brighter future? Hum Vaccin Immunother. 2022;18(4):2079322. https:\/\/doi.org\/10.1080\/21645515.2022.2079322.","journal-title":"Hum Vaccin Immunother"},{"key":"1194_CR43","unstructured":"Health Information and Quality Authority (HIQA). Rapid health technology assessment of immunisation against respiratory syncytial virus (RSV) in Ireland; 2024."},{"key":"1194_CR44","unstructured":"Office for National Statistics. Table 2: Live births: month of occurrence, 1938 to 2019. Secondary Table 2: Live births: month of occurrence, 1938 to 2019 2019. https:\/\/www.ons.gov.uk\/file?uri=%2fpeoplepopulationandcommunity%2fbirthsdeathsandmarriages%2flivebirths%2fdatasets%2fbirthcharacteristicsinenglandandwales%2f2019\/birthcharacteristics201912112020134444.xls. Accessed 1 Mar 2025."},{"key":"1194_CR45","unstructured":"Office for National Statistics. Table 8: Births by gestational age at birth and ethnicity of live births, 2019. Secondary Table 8: Births by gestational age at birth and ethnicity of live births, 2019 2019. https:\/\/www.ons.gov.uk\/file?uri=%2fpeoplepopulationandcommunity%2fbirthsdeathsandmarriages%2flivebirths%2fdatasets%2fbirthcharacteristicsinenglandandwales%2f2019\/birthcharacteristics201912112020134444.xls. Accessed 1 Mar 2025."},{"key":"1194_CR46","unstructured":"UK Health Security Agency (UKHSA). Respiratory Syncytial Virus (RSV) Vaccine Patient Group Direction (PGD); 2024."},{"issue":"8","key":"1194_CR47","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1016\/S2468-2667(17)30103-2","volume":"2","author":"D Cromer","year":"2017","unstructured":"Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017;2(8):e367\u201374. https:\/\/doi.org\/10.1016\/S2468-2667(17)30103-2.","journal-title":"Lancet Public Health"},{"issue":"8","key":"1194_CR48","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1017\/S0950268807009557","volume":"136","author":"EK Ajayi-Obe","year":"2008","unstructured":"Ajayi-Obe EK, Coen PG, Handa R, et al. Influenza A and respiratory syncytial virus hospital burden in young children in East London. Epidemiol Infect. 2008;136(8):1046\u201358. https:\/\/doi.org\/10.1017\/S0950268807009557.","journal-title":"Epidemiol Infect"},{"issue":"Suppl 1","key":"1194_CR49","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1093\/infdis\/jiac064","volume":"226","author":"X Li","year":"2022","unstructured":"Li X, Bilcke J, Vazquez Fernandez L, et al. Cost-effectiveness of respiratory syncytial virus disease prevention strategies: maternal vaccine versus seasonal or year-round monoclonal antibody program in Norwegian children. J Infect Dis. 2022;226(Suppl 1):S95\u2013101. https:\/\/doi.org\/10.1093\/infdis\/jiac064.","journal-title":"J Infect Dis"},{"key":"1194_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-024-03782-4","author":"KS Ma","year":"2025","unstructured":"Ma KS, Tsai SY, El Saleeby CM, Kotton CN, Mansbach JM. Nirsevimab decreased the subsequent risk of respiratory syncytial virus infection and wheezing in the 2023\u20132024 RSV season. Pediatr Res. 2025. https:\/\/doi.org\/10.1038\/s41390-024-03782-4.","journal-title":"Pediatr Res"},{"issue":"5","key":"1194_CR51","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00431-019-03564-9","volume":"179","author":"R Thwaites","year":"2020","unstructured":"Thwaites R, Buchan S, Fullarton J, et al. Clinical burden of severe respiratory syncytial virus infection during the first 2 years of life in children born between 2000 and 2011 in Scotland. Eur J Pediatr. 2020;179(5):791\u20139. https:\/\/doi.org\/10.1007\/s00431-019-03564-9.","journal-title":"Eur J Pediatr"},{"key":"1194_CR52","volume-title":"Guide to the methods of technology appraisal","author":"National Institute for Health and Care Excellence","year":"2004","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Care Excellence; 2004."},{"key":"1194_CR53","unstructured":"Office for National Statistics. Child and infant mortality in England and Wales: 2019. Secondary Child and infant mortality in England and Wales: 2019. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/childhoodinfantandperinatalmortalityinenglandandwales\/2019."},{"issue":"6","key":"1194_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009337","volume":"6","author":"S Taylor","year":"2016","unstructured":"Taylor S, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK. BMJ Open. 2016;6(6): e009337. https:\/\/doi.org\/10.1136\/bmjopen-2015-009337.","journal-title":"BMJ Open"},{"key":"1194_CR55","volume-title":"Unit costs of health and social care 2020","author":"L Curtis","year":"2020","unstructured":"Curtis L, Burns A. Unit costs of health and social care 2020. Canterbury: Personal Social Services Research Unit, University of Kent; 2020."},{"key":"1194_CR56","unstructured":"Office for National Statistics. Births in England and Wales: summary tables. Secondary Births in England and Wales: summary tables. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/livebirths\/datasets\/birthsummarytables. Accessed 1 Mar 2025."},{"key":"1194_CR57","unstructured":"National Records of Scotland. Vital Events\u2014Births. Secondary Vital Events\u2014Births. https:\/\/www.nrscotland.gov.uk\/statistics-and-data\/statistics\/statistics-by-theme\/vital-events\/births. Accessed 1 Mar 2025."},{"key":"1194_CR58","unstructured":"Northern Ireland Statistics and Research Agency. Registrar General Annual Report 2021 Births. Secondary Registrar General Annual Report 2021 Births. https:\/\/www.nisra.gov.uk\/publications\/registrar-general-annual-report-2021-births. Accessed 1 Mar 2025."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01194-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01194-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01194-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:56:54Z","timestamp":1754913414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01194-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1194"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01194-3","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mersha Chetty, Paul Costello and Mehdi Ghemmouri are employees of Sanofi and may hold shares and\/or stock options in the company. Benjamin Yarnoff and Robert Musci are salaried employees of Evidera, Inc. and are not allowed to accept remuneration from any clients for their services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}